Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General transcription factor IIi pseudogene 4 (GTF2IP4) is a non-functional genetic element on chromosome 7 (7q11.23), related to the functional transcription factor GTF2I. Unlike GTF2I, GTF2IP4 does not encode a protein and is considered a pseudogene. Some studies investigate RNA editing events on GTF2IP4 transcripts in diseases like Alzheimer’s disease, suggesting a potential, though indirect, regulatory role. However, there is no evidence that GTF2IP4 acts as a therapeutic target, nor is it known to have direct biological or pathological functions via protein products[7]. GTF2IP4 is distinct from GTF2I, which is an established protein-coding gene encoding a transcription factor involved in gene regulation, cell growth, and is implicated in certain diseases such as thymomas and Williams syndrome[1][2][4][5]. Any apparent functional or therapeutic relevance likely refers erroneously to GTF2I, not GTF2IP4. There is no evidence supporting the use of GTF2IP4 as a therapeutic target or biomarker, and the entry may be included incorrectly if intended as a drug target or protein receptor[7].
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General transcription factor IIi pseudogene 4 (GTF2IP4).